Ocugen Inc. (OCGN): Price and Financial Metrics


Ocugen Inc. (OCGN): $2.86

0.09 (+3.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OCGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OCGN Stock Price Chart Interactive Chart >

Price chart for OCGN

OCGN Price/Volume Stats

Current price $2.86 52-week high $17.65
Prev. close $2.77 52-week low $1.67
Day low $2.68 Volume 6,054,200
Day high $2.95 Avg. volume 9,139,308
50-day MA $2.46 Dividend yield N/A
200-day MA $4.06 Market Cap 616.79M

Ocugen Inc. (OCGN) Company Bio


Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.


OCGN Latest News Stream


Event/Time News Detail
Loading, please wait...

OCGN Latest Social Stream


Loading social stream, please wait...

View Full OCGN Social Stream

Latest OCGN News From Around the Web

Below are the latest news stories about Ocugen Inc that investors may wish to consider to help them evaluate OCGN as an investment opportunity.

Ocugen Q4 2021 Earnings Preview

Ocugen (NASDAQ:OCGN) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close. The consensus EPS Estimate is -$0.07 and the consensus Revenue Estimate is $0M. Ahead of its earnings, Ocugen announced a capital raise of $53.5M. Last week, Ocugen announced that the U.S. FDA lifted the...

Seeking Alpha | February 24, 2022

Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The Course

Investment Thesis Ocugen (OCGN) stock has been sinking like a stone since the turn of the year - at the time of writing, it's down >60% in the past three months. This week, the FDA lifted its clinical hold on Ocugen's Investigational New Drug ("IND") application for Covaxin - a...

Edmund Ingham on Seeking Alpha | February 24, 2022

Ocugen expects $53.5M from stock sale amid efforts to bring Covaxin to the U.S.

Ocugen is continuing its efforts to bring a Covid-19 vaccine developed in India to the United States.

Yahoo | February 24, 2022

3 Growth Stocks With Monster Upside of 253% to 650%, According to Wall Street

Select analysts and investment banks are looking for these fast-growing stocks to skyrocket in 2022.

Yahoo | February 24, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader!

William White on InvestorPlace | February 23, 2022

Read More 'OCGN' Stories Here

OCGN Price Returns

1-mo -7.74%
3-mo 43.00%
6-mo -18.52%
1-year -63.61%
3-year -74.44%
5-year -97.35%
YTD -37.14%
2021 148.63%
2020 251.92%
2019 -90.37%
2018 -95.61%
2017 22.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4808 seconds.